Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol

To evaluate the effectiveness and safety of immune checkpoint inhibitors in people with stage I to III NSCLC who receive surgery or radiotherapy with curative intent.

This is a protocol.

Share/Save